An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Trial Profile

An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Suspended
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Voruciclib (Primary) ; Vemurafenib
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Piramal Enterprises
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2015 Interim results (n=9) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Sep 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top